<DOC>
	<DOCNO>NCT00497991</DOCNO>
	<brief_summary>The purpose study assess safety tolerability multiple ascending dos AZD1152 ass effect AZD1152 rate complete remission patient relapse acute myeloid leukaemia .</brief_summary>
	<brief_title>Safety , Tolerability , PK Efficacy AZD1152 Patients With Relapsed Acute Myeloid Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>Relapsed refractory AML standard therapy anticipate result durable remission Newly diagnose AML consider suitable treatment . Previous myeloablative therapy allogeneic bone marrow stem cell transplantation , radiotherapy chemotherapy within 4 week first dose . Participation trial investigational product within previous 30 day Other active malignancy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>AML</keyword>
	<keyword>phase I/II</keyword>
	<keyword>AZD1152</keyword>
	<keyword>Acute Myeloid Leukaemia</keyword>
</DOC>